Close
To find more information on UCLH CRF Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.
GO42144A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies | |
|---|---|
| IRAS Number: | 292846 |
| Principal Investigator: | Dr. Martin Forster |
| Drug Class/ Treatment: | AZD7648 (KRAS G12C Inhibitor) Monotherapy and Combination with Anti-Cancer Therapies |
| Patient Population: | Advanced or Metastatic Solid Tumours with KRAS G12c Mutation |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
IMC-F106C-101A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers | |
|---|---|
| IRAS Number: | 275567 |
| Principal Investigator: | Dr. Heather Shaw |
| Drug Class/ Treatment: | IMC-F106C (Bispecific Antibody against HLA-A*02:01) |
| Patient Population: | HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
GARNETA Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors. | |
|---|---|
| IRAS Number: | 219540 |
| Principal Investigator: | Dr. Rowan Miller |
| Drug Class/ Treatment: | TSR-042 (Dorstarlimab) (Anti PD-L1 Monoclonal Antibody) |
| Patient Population: | Advanced Solid Tumours Cohort F - Patients with Recurrent or Advanced Non-endometrial and non-GI dMMR/MSI-H Solid Tumours or POLE-Mut Cancers |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
MODI-1-001Modi-1 in Patients with Breast, Head & Neck, Ovarian or Renal Cancer: A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer | |
|---|---|
| IRAS Number: | 298608 |
| Principal Investigator: | Dr. Rowan Miller |
| Drug Class/ Treatment: | Modi-1 - Novel Cancer Vaccine |
| Patient Population: | Advanced Solid Tumours:
|
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
TAK-676-1002An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors | |||
|---|---|---|---|
| IRAS Number: | 1006372 | ||
| Principal Investigator: | Professor Martin Forster | ||
| Drug Class/ Treatment: | TAK-676 (Novel Stimulator of Interferon Genes (STING) Single Agent and in Combination with Pembrolizumab | ||
| Patient Population: | Advanced Solid Tumours:
| ||
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |||
EP0031-101A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies | |
|---|---|
| IRAS Number: | 1006061 |
| Principal Investigator: | Professor Martin Forster |
| Drug Class/ Treatment: | EP0031-101 (Selective RET Inhibitor) |
| Patient Population: | Advanced RET-Altered Malignancies
|
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
Mobilize (mRNA-4359-P101)Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors | |
|---|---|
| IRAS Number: | 1007567 |
| Principal Investigator: | Professor Martin Forster |
| Drug Class/ Treatment: | mRNA-4359-P101 (Checkpoint mRNA cancer vaccine) Combination with Checkpoint Inhibitors:
|
| Patient Population: | Advanced Solid Tumours:
|
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
GTAEXS617-001A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors | |
|---|---|
| IRAS Number: | 1006825 |
| Principal Investigator: | Professor Martin Forster |
| Drug Class/ Treatment: | GTAEXS617 (Selective CDK7 Inhibitor) Dose Escalation |
| Patient Population: | Advanced Solid Tumours |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
SGNEGFRd2-001A Phase 1 Study of SGN-EGFRd2 in Advanced Solid Tumors | |
|---|---|
| IRAS Number: | 1008649 |
| Principal Investigator: | Professor Martin Forster |
| Drug Class/ Treatment: | SGN-EGFRd2 (anti-EGFR Gamma Delta T-Cell Engaging Bispecific Antibody) Dose Escalation |
| Patient Population: | Advanced Solid Tumours |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
DETERMINEAn Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations | |||
|---|---|---|---|
| IRAS Number: | 1004057 | ||
| Principal Investigator: | Dr Martin Forster | ||
| Drug Class/ Treatment: |
| ||
| Patient Population: | Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations:
| ||
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |||
